{"id":47431,"date":"2022-08-18T14:01:53","date_gmt":"2022-08-18T12:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/"},"modified":"2022-08-18T14:01:53","modified_gmt":"2022-08-18T12:01:53","slug":"woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/","title":{"rendered":"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–#capitalraise<\/a>—Woebot Health<\/a> today announced that it has appointed Robbert Zusterzeel, M.D., Ph.D., M.P.H., as Vice President of Regulatory Science and Strategy. Reporting to Founder and President Alison Darcy, Zusterzeel will lead the regulatory and scientific strategy for the company\u2019s portfolio of behavioral health and regulated products to ensure they are founded on the highest standards of quality, safety and efficacy. Woebot Health\u2019s products include: the behavioral health solution Woebot<\/a>; WB001, an investigational digital therapeutic for postpartum depression that was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) in 2021; and WB002, an investigational device intended for adolescent depression.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nDarcy said the company\u2019s range of products reflects a rapidly shifting, complex environment that is struggling to meet unprecedented demand for mental health services. \u201cSoftware-based medical devices represent an important public health opportunity to reduce the burden of mental health challenges by making efficacious therapeutics accessible at scale,\u201d said Darcy. \u201cWe believe in and have embraced regulation from the start and have expanded our science-based product organization, which makes it the perfect time to add deep expertise to accelerate the process toward clearance. Robbert\u2019s unique mix of clinical, scientific and regulatory skills and passion for this emerging space will be instrumental in bringing our clinically-proven products to market.\u201d\n<\/p>\n

\nZusterzeel\u2019s expertise focuses on evidence generation across the entire product lifecycle, from computational modeling to adaptive clinical trials and real-world evidence generation. Before joining Woebot Health, he was Senior Director of U.S. Regulatory Science and Strategy at IQVIA, where he co-led, managed and operationalized the U.S. Regulatory Science and Strategy Team to build out evidence solutions for drug, device and biologics development lifecycles.\n<\/p>\n

\nBefore that, Zusterzeel joined the FDA as a Staff Fellow Medical Officer. He spent nearly 10 years at the agency serving as the lead investigator for multiple studies about the cardiac safety of drugs and co-investigator for multiple reviews of the safety and efficacy of medical device therapies. Zusterzeel obtained his M.D. and Ph.D. degrees at Maastricht University\u2019s Faculty of Health, Medicine and Life Sciences in the Netherlands and completed his Master\u2019s of Public Health in Epidemiology at Harvard University\u2019s T.H. Chan School of Public Health. The author of dozens of peer-reviewed publications, book chapters and white papers, Zusterzeel has received numerous honors, awards and grants.\n<\/p>\n

\n\u201cI\u2019ve always been interested in technology and passionate about the use of data to improve our understanding and the development of new treatment areas,\u201d said Zusterzeel. \u201cThe opportunity at Woebot Health brings together my interests in medicine and technology, coupled with novel challenges in the regulatory arena. It\u2019s a great opportunity to help push the field forward in an essential area.\u201d\n<\/p>\n

\nAbout Woebot Health<\/b>\n<\/p>\n

\nWoebot Health is the world\u2019s first mental health ally for people and businesses that puts personal growth in people\u2019s hands, wherever they are. Our pipeline of prescription digital therapeutics and behavioral health products combine artificial intelligence, decades of clinically-proven techniques and a relational agent called Woebot, which together form the foundation for mental health solutions that engage at scale and fit right into people\u2019s lives. For more information, visit woebothealth.com<\/a> or follow Woebot on Facebook<\/a>, Twitter<\/a> and LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMargot Carlson Delogne, margot@woebothealth.com<\/a> (781) 492-1039\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–#capitalraise—Woebot Health today announced that it has appointed Robbert Zusterzeel, M.D., Ph.D., M.P.H., as Vice President of Regulatory Science and Strategy. Reporting to Founder and President Alison Darcy, Zusterzeel will lead the regulatory and scientific strategy for the company\u2019s portfolio of behavioral health and regulated products to ensure they are founded on the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47431","6":"format-standard","7":"category-industry"},"yoast_head":"\nWoebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–#capitalraise—Woebot Health today announced that it has appointed Robbert Zusterzeel, M.D., Ph.D., M.P.H., as Vice President of Regulatory Science and Strategy. Reporting to Founder and President Alison Darcy, Zusterzeel will lead the regulatory and scientific strategy for the company\u2019s portfolio of behavioral health and regulated products to ensure they are founded on the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-18T12:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220818005218\/en\/1547531\/21\/Robbert_Zusterzeel.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy\",\"datePublished\":\"2022-08-18T12:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/\"},\"wordCount\":569,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220818005218\\\/en\\\/1547531\\\/21\\\/Robbert_Zusterzeel.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/\",\"name\":\"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220818005218\\\/en\\\/1547531\\\/21\\\/Robbert_Zusterzeel.jpg\",\"datePublished\":\"2022-08-18T12:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220818005218\\\/en\\\/1547531\\\/21\\\/Robbert_Zusterzeel.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220818005218\\\/en\\\/1547531\\\/21\\\/Robbert_Zusterzeel.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/","og_locale":"en_US","og_type":"article","og_title":"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–#capitalraise—Woebot Health today announced that it has appointed Robbert Zusterzeel, M.D., Ph.D., M.P.H., as Vice President of Regulatory Science and Strategy. Reporting to Founder and President Alison Darcy, Zusterzeel will lead the regulatory and scientific strategy for the company\u2019s portfolio of behavioral health and regulated products to ensure they are founded on the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-18T12:01:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220818005218\/en\/1547531\/21\/Robbert_Zusterzeel.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy","datePublished":"2022-08-18T12:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/"},"wordCount":569,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220818005218\/en\/1547531\/21\/Robbert_Zusterzeel.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/","url":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/","name":"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220818005218\/en\/1547531\/21\/Robbert_Zusterzeel.jpg","datePublished":"2022-08-18T12:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220818005218\/en\/1547531\/21\/Robbert_Zusterzeel.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220818005218\/en\/1547531\/21\/Robbert_Zusterzeel.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/woebot-health-appoints-robbert-zusterzeel-as-vice-president-of-regulatory-science-and-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Woebot Health Appoints Robbert Zusterzeel as Vice President of Regulatory Science and Strategy"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47431"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47431\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}